| HY01.01LB | VRC01 antibody prevention of HIV | Oral Abstract Session | Clinical trial results |
| HY01.02LB | Long acting injectable cabotegravir is safe and effective in preventing HIV infection in cisgender women: interim results from HPTN 084 | Oral Abstract Session | Clinical trial results |
| OA01.01 | Evaluation of the kinetics of systemic distribution of IV injected monoclonal antibodies modified to alter host mediated Fc interaction in the rhesus macaque model | Oral Abstract Session | Broadly neutralizing antibodies |
| OA01.02 | Monoclonal antibodies with ultra-long CDRH3 derived from vaccinated cows show exceptional neutralisation potency and breadth that is retained after Fc engineering | Oral Abstract Session | Humoral immunity |
| OA01.03 | Fc?RIIa rs10800309 polymorphism is a HLA-B57 and HLA-B27 independent predictor of HIV control | Oral Abstract Session | Humoral immunity |
| OA01.04 | Serum IgA inhibits HIV-specific broadly neutralising antibody Fc functions | Oral Abstract Session | Broadly neutralizing antibodies |
| OA01.05LB | Opening the HIV-1 envelope for neutralization and antibody-dependent cellular cytotoxicity | Oral Abstract Session | Therapeutic vaccines, viral reservoirs and eradication/remission |
| OA02.01 | Profiling the HIV epidemic with recency of infection instead of recency of diagnosis: 2 years of experience in North Carolina, USA | Oral Abstract Session | Epidemiology of HIV |
| OA02.02 | Correlates of high HIV transmission areas in a generalized hyperendemic setting: findings from a national survey in Eswatini | Oral Abstract Session | Treatment as prevention |
| OA02.03 | Progress toward HIV elimination goals: trends in and projections of treatment as prevention strategy in 38 African countries | Oral Abstract Session | Treatment as prevention |
